Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LADII: Labor and Delivery Implant Insertion
NCT02866643Phase 3Completed
- Sponsor
- Stanford University
- Start
- Oct 2016
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etonogestrel in contraception (2 arms), sponsored by Stanford University. Primary endpoint: Time to Lactogenesis Stage II at 7 days. Started Oct 2016; status: completed.
02
Drugs
etonogestrel
03
Conditions
contraception
Beyond the preview
Go deeper on NCT02866643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866643.